A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.

In the SEQUOIA trial, the BTK inhibitor zanubrutinib (Brukinsa) was delivered as a continuous dose in frontline chronic ...

Karen Fancher, PharmD, BCOP, associate professor of pharmacy practice at Duquesne University and clinical oncology specialist ...

The EMA has recommended label expansions for Inaqovi, Opdivo, and Venclyxto, broadening treatment options in AML, Hodgkin lymphoma, and CLL.

Tanya Siddiqi, MD, shares her personal experience using continuous BTK inhibitor therapy for the treatment of patients with ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.

In a study of patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (CLL/SLL) who do not have 17p deletions, Jaypirca topped the chemoimmunotherapy combination ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.